Development of a new drug delivery system for protein drugs using silicone (II)

被引:44
作者
Kajihara, M
Sugie, T
Hojo, T
Maeda, H
Maeda, H
Sano, A
Fujioka, K
Sugawara, S
Urabe, Y
机构
[1] Sumitomo Pharmaceut Co Ltd, Res Ctr, Ibaraki, Osaka 5670878, Japan
[2] Dow Corning Asia Ltd, Chiyoda Ku, Tokyo 1000005, Japan
关键词
zero-order; covered-rod; interferon; silicone; release mechanism;
D O I
10.1016/S0168-3659(01)00302-9
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
In order to achieve a zero-order release of protein drugs, we have developed a new drug delivery system using silicone, which is named the covered-rod-type formulation. Preparation of the covered-rod-type formulation was conducted under mild conditions without heat treatment or the use of organic solvents. The covered-rod-type formulation released human serum albumin (HSA) or interferon (IFN) at a constant rate for 30-100 days in vitro without significant initial burst. When the IFN covered-rod-type formulation was implanted in nude mice, the serum IFN concentration was maintained at a constant level during the period of observation, i.e., 28 days. The covered-rod-type formulation enabled precise control of the release of the protein drugs and would be expected to increase the duration of the drug effect and to reduce the frequency of administration and side effects. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:279 / 291
页数:13
相关论文
共 15 条
[1]   Recombinant human growth hormone poly(lactic-co-glycolic acid) microsphere formulation development [J].
Cleland, JL ;
Johnson, OL ;
Putney, S ;
Jones, AJS .
ADVANCED DRUG DELIVERY REVIEWS, 1997, 28 (01) :71-84
[2]  
DIONNE KE, 1996, P INT S CONTRL REL B, V23, P271
[3]   A large-scale process to produce microencapsulated proteins [J].
Herbert, P ;
Murphy, K ;
Johnson, O ;
Dong, N ;
Jaworowicz, W ;
Tracy, MA ;
Cleland, JL ;
Putney, SD .
PHARMACEUTICAL RESEARCH, 1998, 15 (02) :357-361
[4]   A month-long effect from a single injection of microencapsulated human growth hormone [J].
Johnson, OL ;
Cleland, JL ;
Lee, HJ ;
Charnis, M ;
Duenas, E ;
Jaworowicz, W ;
Shepard, D ;
Shahzamani, A ;
Jones, AJS ;
Putney, SD .
NATURE MEDICINE, 1996, 2 (07) :795-799
[5]   The stabilization and encapsulation of human growth hormone into biodegradable microspheres [J].
Johnson, OL ;
Jaworowicz, W ;
Cleland, JL ;
Bailey, L ;
Charnis, M ;
Duenas, E ;
Wu, CC ;
Shepard, D ;
Magil, S ;
Last, T ;
Jones, AJS ;
Putney, SD .
PHARMACEUTICAL RESEARCH, 1997, 14 (06) :730-735
[6]   Development of new drug delivery system for protein drugs using silicone (I) [J].
Kajihara, M ;
Sugie, T ;
Mizuno, M ;
Tamura, N ;
Sano, A ;
Fujioka, K ;
Kashiwazaki, Y ;
Yamaoka, T ;
Sugawara, S ;
Urabe, Y .
JOURNAL OF CONTROLLED RELEASE, 2000, 66 (01) :49-61
[7]   PRESENT AND FUTURE APPLICATIONS OF BIOMATERIALS IN CONTROLLED DRUG DELIVERY SYSTEMS [J].
LANGER, RS ;
PEPPAS, NA .
BIOMATERIALS, 1981, 2 (04) :201-214
[8]   SUSTAINED PHARMACOLOGICAL ACTIVITIES IN RATS FOLLOWING SINGLE AND REPEATED ADMINISTRATION OF ONCE-A-MONTH INJECTABLE MICROSPHERES OF LEUPROLIDE ACETATE [J].
OKADA, H ;
HEYA, T ;
OGAWA, Y ;
TOGUCHI, H ;
SHIMAMOTO, T .
PHARMACEUTICAL RESEARCH, 1991, 8 (05) :584-587
[9]   One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate [J].
Okada, H .
ADVANCED DRUG DELIVERY REVIEWS, 1997, 28 (01) :43-70
[10]  
OKADA H, 1989, P INT S CONTROL REL, V16, P12